OBJECTIVE: This prospective study examines the effect of clozapine on glucose control and insulin sensitivity. METHOD: Glucose homeostasis was measured in nine female and 11 male patients with schizophrenia (mean age=30.5 years, SD=7.4) before clozapine treatment and after a mean of 2.5 months (SD=0.95) of clozapine treatment. Oral glucose tolerance and insulin levels were measured. Insulin resistance level was measured by the homeostasis model assessment. RESULTS: Eleven (55%) of the patients developed abnormal glucose control; the mean age of these patients was 30.2 (SD=7.1), and five were women. Patients' insulin resistance at baseline (mean insulin resistance level=3.88, SD=2.93) was unaffected by clozapine. Mean fasting and 2-hour glucose levels significantly increased by 0.55 mmol/liter and 1.4 mmol/liter, respectively. There was no correlation between change in body mass index and change in fasting glucose levels. CONCLUSIONS: Clozapine impairs glucose control within 4 months of treatment, independent of changes in insulin sensitivity and body mass index.
OBJECTIVE: This prospective study examines the effect of clozapine on glucose control and insulin sensitivity. METHOD: Glucose homeostasis was measured in nine female and 11 male patients with schizophrenia (mean age=30.5 years, SD=7.4) before clozapine treatment and after a mean of 2.5 months (SD=0.95) of clozapine treatment. Oral glucose tolerance and insulin levels were measured. Insulin resistance level was measured by the homeostasis model assessment. RESULTS: Eleven (55%) of the patients developed abnormal glucose control; the mean age of these patients was 30.2 (SD=7.1), and five were women. Patients' insulin resistance at baseline (mean insulin resistance level=3.88, SD=2.93) was unaffected by clozapine. Mean fasting and 2-hour glucose levels significantly increased by 0.55 mmol/liter and 1.4 mmol/liter, respectively. There was no correlation between change in body mass index and change in fasting glucose levels. CONCLUSIONS: Clozapine impairs glucose control within 4 months of treatment, independent of changes in insulin sensitivity and body mass index.
Authors: D C Henderson; E Cagliero; C Gray; R A Nasrallah; D L Hayden; D A Schoenfeld; D C Goff Journal: Am J Psychiatry Date: 2000-06 Impact factor: 18.112
Authors: Michael J Sernyak; Douglas L Leslie; Renato D Alarcon; Miklos F Losonczy; Robert Rosenheck Journal: Am J Psychiatry Date: 2002-04 Impact factor: 18.112
Authors: John W Newcomer; Dan W Haupt; Robert Fucetola; Angela K Melson; Julie A Schweiger; Benjamin P Cooper; Gregg Selke Journal: Arch Gen Psychiatry Date: 2002-04
Authors: E Bonora; S Kiechl; J Willeit; F Oberhollenzer; G Egger; G Targher; M Alberiche; R C Bonadonna; M Muggeo Journal: Diabetes Date: 1998-10 Impact factor: 9.461
Authors: Oliver D Howes; Shubulade Smith; Fiona P Gaughran; Stephanie A Amiel; Robin M Murray; Lyn S Pilowsky Journal: J Clin Psychopharmacol Date: 2006-12 Impact factor: 3.153
Authors: Oliver D Howes; Fiona P Gaughran; Stephanie A Amiel; Robin M Murray; Lyn S Pilowsky Journal: J Clin Psychiatry Date: 2004-10 Impact factor: 4.384